Jan Oliver Staak

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

U. Rehwald, H. Schulz, Marcel Reiser et al. · Blood · 2002 · 144 citations · Full text

Medicine, Immunology, Oncology +16

Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131–Labeled Murine Anti-CD30 Monoclonal Antibody

Roland Schnell, Markus Dietlein, Jan Oliver Staak et al. · Journal of Clinical Oncology · 2005 · 117 citations

Medicine, Nuclear Medicine, Oncology +17

Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin’s lymphoma

R. Schnell, Peter Borchmann, Jan Oliver Staak et al. · Annals of Oncology · 2003 · 100 citations · Full text

Medicine, Immunology, Oncology +13

Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphoma

Peter Borchmann, R. Schnell, R Knippertz et al. · Annals of Oncology · 2001 · 52 citations · Full text

Medicine, Oncology, Chemotherapy +12

Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma

Jan‐Peter Glossmann, Jan Oliver Staak, Lucia Nogová et al. · Annals of Hematology · 2005 · 14 citations

Medicine, Immunology, Oncology +15